Showing results (501-510 of 538) with videos related to
Sort By:
Pageof 54
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 8, 2020
Rhabdoid Tumors Are Sensitive to the Protein-Translation Inhibitor HomoharringtonineThomas P Howard, Elaine M Oberlick, Matthew G Rees, et al.Biorxiv : the Preprint Server for Biology|August 6, 2025
Discovery of chromatin-based determinants of azacytidine and decitabine anti-cancer activityRishi V Puram, Qiangzong Yin, YuhJong Liu, et al.ACS Central Science|April 27, 2026
Proximity-Induced Rewiring of Oncogenic Kinase Triggers ApoptosisManuel L Merz, Veronika M Shoba, Rajaiah Pergu, et al.Cancer Research|May 22, 2026
Genetic Drivers of Sensitivity or Resistance to RAS(ON) Multi-Selective Inhibitors in NRAS-Mutated MelanomaMona Foth, Wontak Kim, Kayla O'Toole, et al.Nature Cancer|December 27, 2023
Small-molecule inhibition of kinesin KIF18A reveals a mitotic vulnerability enriched in chromosomally unstable cancersMarc Payton, Brian Belmontes, Kelly Hanestad, et al.Cancer Discovery|July 14, 2026
CDK8 Inhibition Releases the Muscle Differentiation Block in Fusion-driven Alveolar RhabdomyosarcomaSusu Zhang, Kathleen L Engel, Assil Fahs, et al.Nature Chemical Biology|December 15, 2015
Correlating chemical sensitivity and basal gene expression reveals mechanism of actionMatthew G Rees, Brinton Seashore-Ludlow, Jaime H Cheah, et al.Molecular Cancer Therapeutics|December 8, 2023
4'-Ethynyl-2'-Deoxycytidine (EdC) Preferentially Targets Lymphoma and Leukemia Subtypes by Inducing Replicative StressMarissa L Calbert, Gurushankar Chandramouly, Clare M Adams, et al.Cancer Discovery|September 2, 2025
Defining the antitumor mechanism of action of a clinical-stage compound as a selective degrader of the nuclear pore complexLinjie Yuan, Wenzhi Ji, Brendan G Dwyer, et al.Cancer Research|February 14, 2019
MDM2 and MDM4 Are Therapeutic Vulnerabilities in Malignant Rhabdoid TumorsThomas P Howard, Taylor E Arnoff, Melinda R Song, et al.Pageof 54